Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study

Arğun, Derya; Basım, Pelin; Uysal, Betül Börkü; Argun, Ferit

doi:10.28982/josam.859388

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased HbA1c is a crucial marker of persistently high blood sugar and contributes to a chain reaction of diseases brought on by vascular damage [15] In this cross-sectional study we have measured preptin levels in T2DM patients with NAFLD. Insulin resistance plays a signi cant part in the development of type 2 diabetes, which in turn causes an increase in the amount of insulin that is secreted by beta cells in the pancreas in order to make up for the higher levels of glucose in the blood.…”

Section: Discussionmentioning

confidence: 99%

Association of preptin and glycemic status in individuals with non-alcoholic fatty liver

A.,

et al. 2024

Preprint

View full text Add to dashboard Cite

Context: Preptin is a hormone which is co-secreted with insulin and amylin from beta cells of pancreas. Non-alcoholic fatty liver is a disorder in which there's excessive fat accumulation in the liver cells without evidence of alcohol consumption. Both T2DM and NAFLD is associated with various peptide hormone, but the association of preptin with Non-alcoholic fatty liver and it’s different stages is still not clear. Aim and objective: To determine the level of preptin in T2DM patients with NAFLD and to assess the levels of liver enzymes. To correlate preptin levels with liver enzymes and stages of NAFLD. Settings and Design: Analytical cross sectional study Methods and Material: This is an analytical cross sectional study comprising of 64 T2DM patients divided into two groups based on their glycemic controls with HbA1c more than 8%, ALT ≤ 40 IU/L and ALT ≥ 40 IU/L in SRM Medical College Hospital and Research Centre Diabetology OP and MHC in the age group of 35-80. Statistical analysis used: The data was analysed using statistical package of social service (SPSS 26.0). Results: Plasma preptin levels are increased in patients with T2DM and NAFLD. The NAFLD score and TyG index showed a positive correlation in participants in group 2. In group 2 patients there is a positive correlation between NAFLD score and AST, ALT, ALP, GGT, while TyG index shows a positive correction with LDL and VLDL in both groups. Conclusions: Preptin may have a role in the pathophysiology of NAFLD and may be a valuable marker in predicting fibrosis development along with NAFLD score.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of preptin and glycemic status in individuals with non-alcoholic fatty liver

A.,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities

Abdurahmanov¹,

Güntürk²,

Kartufan³

et al. 2021

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Background/Aim: Non-alcoholic fatty liver is quite common among modern populations, and simpler methods are researched for its early diagnosis and therapy. Studies are stating that vitamin D deficiency could play a role in the etiopathogenesis of fatty liver. This study aimed to compare the efficacy of metformin and vitamin D therapy in improving fatty liver disease. Methods: A total of 86 patients with non-alcoholic fatty liver disease were included in this case control study and classified into four groups according to the treatment received. In the study group, 23 patients were using metformin only, and 21 patients were using both metformin and vitamin D. Twenty-one patients were using vitamin D only, and 21 patients were on a diet and an exercise regimen (control group). Weight, BMI, waist circumference, fatty liver index (FLI), HOMA-IR, AST, ALT, GGT, triglyceride parameters were evaluated before and after four weeks of therapy. Results: There was a significant regression in the fatty liver disease of the patients who used both metformin and vitamin D (FLI-%5, 90 (11.1) P=0.025). Among patients who used only metformin and only vitamin D, the decrease in FLI was not significant (P>0.05); however, FLI was observed to significantly decrease in the control group (-7.30, P=0.018). The serum CRP levels were also observed to significantly decrease in the control, Met and Met-D vit groups (P=0.025, P=0.002, P=0.006, respectively). Conclusions: The combination of vitamin D and metformin therapy could positively contribute to the improvement of NAFLD in patients with vitamin D deficiency.

show abstract

Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study

Cited by 2 publications

References 22 publications

Association of preptin and glycemic status in individuals with non-alcoholic fatty liver

Association of preptin and glycemic status in individuals with non-alcoholic fatty liver

Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities

Contact Info

Product

Resources

About